Figure 5.

Effect of TCTP and the HMGB1-TLR4/RAGE-NF-κB pathway on the invasion potential of LoVo cells (magnification, ×400). The invasive capacity of LoVo NC cells (middle), LoVo TCTP-O cells (left) or LoVo-TCTP-K (right) were assessed by a cell invasion assay. The number of invasive cells was quantified by visual counting of six randomly selected fields. The groups comprised cells left untreated as controls, cells treated with rhHMGB1 (10 μg/ml) or anti-HMGB1, anti-TLR4, anti-RAGE (all 5 μg/ml) or the specific NF-κB inhibitor Bay117082 (5 μmol/l), respectively. ^**P<0.01, compared with untreated cells. Similar results were obtained in four independent experiments. LoVo-NC, normal control LoVo cells; TCTP-K, LoVo cells transfected with TCTP-knockdown vector; TCTP-O, LoVo cells transfected with TCTP-overexpression vector; TCTP, translationally controlled tumor protein; HMGB1, high mobility group box 1; rhHMGB1, recombinant human HMGB1; NF-κB, nuclear factor-κB; TLR4, Toll-like receptor 4; RAGE, receptor for advanced glycation end products.